Cardiovascular (CV) risk after initiation of abatacept versus TNF inhibitors in rheumatoid arthritis patients with and without baseline CV disease
Jin Y et al. J Rheumatol 2018. doi: 10.3899/jrheum.170926
Please follow the link below to view this article in full on a third-party website. Note that a subscription or payment may be required.